Загрузка...

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway

Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib i...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncol Res
Главные авторы: Tan, Wenliang, Zhu, Sicong, Cao, Jun, Zhang, Lei, Li, Wenda, Liu, Kairui, Zhong, Jinyi, Shang, Changzhen, Chen, Yajin
Формат: Artigo
Язык:Inglês
Опубликовано: Cognizant Communication Corporation 2017
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841021/
https://ncbi.nlm.nih.gov/pubmed/28276313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504017X14886444100783
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!